Cytovation, a Bergen, Norway-based clinical stage immune-oncology company, raised $8M in Series A extension funding.
The round, which brought total Series A funding to over $28m, was co-led by existing investors Sandwater, and Canica.
The company intends to use the funds to support the progress of its lead asset, CyPep-1, into a full Phase 2 program for the treatment of solid tumors.
Led by Lars Prestegarden, MD, PhD, CEO, Cytovation is a clinical stage immune-oncology company focused on the development of CyPep-1, an immunotherapy targeting the cell membrane of tumor cells. CyPep-1 has a multi-modal mechanism of action, eliminating cancer cells by forming pores in the plasma membrane, releasing antigens to the immune system, promoting an inflammatory microenvironment, and inducing a tumor-specific immune response by in situ vaccination.
The company is a spin-off from the University of Bergen (Norway).
FinSMEs
02/06/2023